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In Brazil, the Law 9787 of February 10, 1999, authorized the commercialization by any pharmaceutical company of drugs, whose patent protection expired, in a standardized 
packaging with a yellow band and a ‘G’ of ‘generic’. Generic 
drugs are usually cheaper, because, after the expiration of the 
patent protection of their brand-name pharmaceutical products, 
manufacturers need neither to invest in clinical research, nor to 
redo the trials that con¿ rm the ef¿ cacy and safety of a certain 
drug. Such costs are inherent to certain phases of the process 
of research and discovery of new pharmaceutical drugs, and 
have already been conducted by the innovator company that 
had ¿ rst obtained patent on a certain drug. Thus, manufactur-
ers of generic drugs can sell their copies with the same quality 
of the brand-name pharmaceutical product at a lower price. 
However, biological drugs differ between themselves regard-
ing complexity and cannot be approved in the same way of 
synthetic generic drugs or with the same criterion used for 
synthetic generics.1
There is worldwide consensus that a similar biothera-
peutic product is a biopharmaceutical product approved via a 
regulatory pathway, which comprises biological and clinical 
comparison with the brand-name product counterpart, in ad-
dition to a strict assessment of its immunogenic potential.2 
These requirements for a biological molecule to be named 
‘similar biotherapeutic product’ is included in the World Health 
Organization (WHO) guidelines on evaluation of similar bio-
therapeutic products, and are considered the minimum condi-
tions required for approval for market and selling.2,3
Similarly to other emerging countries, from the economic 
viewpoint, Brazil has a promising market of similar biothera-
peutic products to manufacturers and/or traders of copies, pa-
tients and payers, including the Federal Government. However, 
the approval for marketing and selling similar biotherapeutic 
products, unlike generic drugs, without the conduction of 
quality clinical trials, represents a real threat to patients. The 
Brazilian Sanitary Surveillance Agency (ANVISA) has estab-
lished a review of its previous normalization to approve similar 
biotherapeutic products by use of the RDC 55, published at the 
end of 2010.4 However, that normalization diverges in certain 
aspects from the WHO guidelines, particularly in establishing 
two regulatory pathways for approval, individual and com-
parative, in the extrapolation of therapeutic indications and in 
differences in the emphasis given to the design and statistical 
considerations of the trials; nevertheless, the practical applica-
tion of the latter has not yet been completely clari¿ ed by that 
agency to the scienti¿ c community.5 
An interesting exercise recently published in the medical 
literature, and conducted in a meeting sponsored by the WHO 
in Seoul, South Korea, illustrates the relevance of the need 
for a case-to-case approach when comparing clinical data 
between similar biotherapeutic products and their brand-name 
pharmaceutical counterparts.6 That is the only way to ensure the 
adequate ef¿ cacy and safety of similar biotherapeutic products 
to any studied indication. 
The fact that small biochemical and biological differ-
ences might cause signi¿ cant clinical differences makes us 
believe that one biosimilar product must at least be as effec-
tive and safe as its brand-name pharmaceutical counterpart. 
Comparative randomized clinical trials are currently consid-
ered the best experimental design to assess treatment-related 
questions.
In a phase 3 study, a similar biotherapeutic product can be 
assessed by use of statistical designs, such as the equivalence 
and non-inferiority approaches comparing them with controls. 
The former has the greatest af¿ nity with the nature of the 
biosimilarity process (to ensure that a similar biotherapeutic 
product is neither more nor less effective than a brand-name 
pharmaceutical product counterpart at the same dose and for 
the same route of administration).7 Non-inferiority studies 
are justi¿ ed and accepted mainly when the innovative prod-
uct already has a large safety margin, and they are aimed at 
determining whether the similar biotherapeutic product is at 
least as effective as its brand-name pharmaceutical product 
counterpart, or even a little less effective, but within a certain 
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pre-established limit, that is, within an acceptable range.8 In 
addition, one copy might have a better ef¿ cacy pro¿ le, above 
that range, but the non-inferiority result will be equally valid. 
Theoretically, a similar biotherapeutic product could be better 
assessed by use of equivalence studies, which are more restrict, 
implying that neither better nor worse results should exist 
within the pre-established range. The non-inferiority margin 
is based on previous studies performed with the brand-name 
pharmaceutical product counterpart, preferably in comparison 
with a placebo.
 It is worth noting that in the non-inferiority study, the popu-
lations studied and the outcomes should be equal to those of 
the study providing the characteristics of the brand-name phar-
maceutical product counterpart. Superiority studies, as shown 
in Figure 1, are not meant to comparison between biological 
innovations and copies, but might be used to demonstrate 
the better ef¿ cacy pro¿ le of molecules known as biobetters. 
Another important aspect relates to the size of the sample 
that should be included in the comparative study between an 
innovation and its copy. That sample size will depend mainly 
on the value stipulated for the non-inferiority margin and data 
variability.9 Very wide non-inferiority or equivalence margins 
usually require small sample sizes, while narrower margins 
require a larger number of patients. Unfortunately, so far the 
sample sizes of non-inferiority or equivalence studies involv-
ing similar biotherapeutic products have been very small. In 
addition, it is worth noting that occasional losses of patients 
per group in a study, mainly due to À aws in the interpreta-
tion of tests and patient’s withdrawal, should be replaced to 
maintain the statistical power of the project. In Brazil, copies 
of recombinant erythropoietin have been approved after an 
open study with 25 patients in phase 1–2a studies.10 Studies 
like those would not be adequate for the current approval of 
copies of fusion proteins or monoclonal antibodies, whose 
patents expire.
The choice of a clinical trial design depends on several 
factors, and the speci¿ c design selected for a particular trial 
should be explicitly justi¿ ed in the protocol of that trial. The 
selection of the endpoints of primary ef¿ cacy and of the 
statistical design of the main study, as well as the calculation 
of the appropriate sample size to ensure statistical power, is 
a multi-step process. To be properly assessed, that process 
requires clear understanding of the comparability margins 
(sometimes called comparability limits or, simply, margins) 
for a certain endpoint, which ultimately translates better ef-
¿ cacy. According to the WHO, the selected margin should 
represent the largest difference in ef¿ cacy/safety that matters 
in clinical practice.
Similarly, regarding the treatment of individuals with 
rheumatoid arthritis, only margins properly de¿ ned to detect 
signi¿ cant differences between a certain anti-TNF biosimilar 
and its brand-name pharmaceutical product counterpart, based 
on the ef¿ cacy measured by the impact of both treatments on 
the ACR20 index, could be accepted. By de¿ nition, any dif-
ference in result contained within that variation would have 
no clinical relevance. By nature, the comparability margins 
for a certain endpoint result from clinical reasoning, being 
frequently neither well established nor universally accepted. 
Thus, the choice of the sample size should be well justi¿ ed by 
the sponsors of the study, being usually a combination of the 
opinion of experts and previously published analyses.
In addition, ANVISA representatives should also agree 
with those margins before the study is initiated. Thus, it 
is understandable that experts of the Brazilian Society of 
Rheumatology, with a large experience in managing patients 
with rheumatoid arthritis and spondyloarthritides, be previ-
ously consulted by the sponsors of the study to provide an 
opinion about and agree on the size of those margins, in cases 
in which the endpoints are related to rheumatic disorders. The 
combination should not be based on ‘guesses’, requiring a deep 
search in the literature about the most impacting clinical out-
comes related to the current treatment of rheumatic disorders.
The scienti¿ c community of Brazilian rheumatology waits 
for the results of high-quality clinical trials developed by 
manufacturers responsible for new biosimilars of biological 
molecules used in their clinical practice.
The author declares receiving no incentive for this article’s 
publication; he reports being part of the advisory boards of the 
Janssen, Abbott and P¿ zer pharmaceutical companies.
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aceitável.8 É possível, inclusive, que uma cópia tenha melhor 
per¿ l de e¿ cácia, acima dessa variação, havendo um bônus, 
mas o resultado de não inferioridade será igualmente válido. 
Por conceito, um biossimilar poderia ser mais bem avaliado 
por estudos de equivalência, pois são mais restritos e implicam 
que não deveria haver resultado nem melhor nem pior, dentro 
da variação preestabelecida. A margem de não inferioridade tem 
base em estudos prévios feitos com o medicamento original, de 
preferência em comparação a placebo.
 No desenho do estudo de não inferioridade, devemos 
lembrar que as populações estudadas e os desfechos devem 
igualmente ao estudo que forneceu as características do com-
parador original. Estudos de superioridade, como demonstrado 
na Figura 1 não se prestam à comparação entre inovadores e 
cópias biológicas, mas podem ser empregados para a demons-
tração de melhor per¿ l de e¿ cácia de moléculas conhecidas 
como biobetters. Outro aspecto importante diz respeito ao 
tamanho da amostra de pacientes que devem ser incluídos no 
estudo comparativo entre um inovador e sua pretensa cópia. 
Esse tamanho amostral dependerá, sobretudo, do valor estipu-
lado para a margem de não inferioridade e da variabilidade dos 
dados.9 Margens de não inferioridade ou de equivalência muito 
amplas requerem, muitas vezes, pequenos tamanhos amostrais, 
enquanto margens mais estreitas requerem maior número de 
pacientes. Infelizmente, os tamanhos amostrais de estudos 
de equivalência ou não inferioridade entre biossimilares, até 
aqui, têm sido frequentemente muito pequenos. Além disso, é 
preciso salientar que eventuais perdas de pacientes por grupo, 
principalmente por conta de falhas na interpretação de exames, 
desligamentos da pesquisa etc., devem ser repostas, de modo 
a manter o poder estatístico do projeto. No Brasil, cópias de 
eritropoetinas recombinantes foram aprovadas após estudo 
aberto com tamanho amostral de 25 pacientes em estudos de 
fase 1–2a.10 Certamente, estudos nesse molde seriam inviáveis 
para a atual aprovação de cópias de proteínas de fusão ou 
anticorpos monoclonais que perdem suas patentes.
A escolha do desenho de um ensaio clínico é dependente 
de muitos fatores, e o desenho especí¿ co selecionado para 
um estudo particular deve ser explicitamente justi¿ cado no 
protocolo do ensaio proposto. A seleção dos endpoints de 
e¿ cácia primária e o desenho estatístico do estudo principal, 
bem como o cálculo do tamanho amostral apropriado para 
assegurar seu poder estatístico, são um processo de muitas 
etapas. Esse processo requer claro entendimento sobre o que 
são as margens de comparabilidade (algumas vezes chamadas 
limites de comparabilidade ou somente margens), para que 
determinado endpoint particular, que traduza melhor e¿ cácia 
em última análise, seja adequadamente avaliado. A OMS muito 
bem explicitou em seus guias que “a margem selecionada deve 
representar a mais larga diferença em e¿ cácia/segurança que 
importa na prática clínica”.
De forma analógica, somente margens adequadamente 
de¿ nidas para detectar diferenças signi¿ cantes no tratamento 
de portadores de artrite reumatoide entre um determinado bios-
similar de um agente anti-TNF e seu comparador, tomando por 
base a e¿ cácia medida por impacto de ambos os tratamentos no 
índice ACR20, poderiam ser aceitas, porque, por de¿ nição, não 
haveria relevância clínica de qualquer diferença de resultado 
que estivesse contido dentro dessa variação. Por natureza, as 
margens de comparabilidade para um dado endpoint são em 
última análise um juízo clínico e frequentemente não estão 
bem-estabelecidas ou universalmente aceitas. Portanto, a 
escolha do tamanho dessa margem deve ser bem-justi¿ cada 
pelos patrocinadores do estudo, usualmente uma combinação 
da opinião de experts e de análises prévias publicadas.
Além disso, representantes da ANVISA também devem 
concordar com elas antes que se inicie o estudo. Dessa for-
ma, faz sentido que especialistas da Sociedade Brasileira de 
Reumatologia, com grande experiência no tratamento de 
portadores de artrite reumatoide e espondiloartrites, sejam 
previamente consultados pelos patrocinadores para opinar 
e concordar com o tamanho dessas margens, nos casos em 
que os endpoints estejam relacionados a tais enfermidades. A 
combinação não deveria ser pautada somente por “achismos”, 
sem um estudo aprofundado da literatura sobre os desfechos 
clínicos mais impactantes relacionados ao tratamento atual de 
enfermidades reumatológicas.
A comunidade cientí¿ ca da reumatologia brasileira aguarda 
os resultados de ensaios clínicos de alta qualidade desenvolvi-
dos por fabricantes responsáveis pela entrada de novos biossi-
milares de moléculas biológicas usadas em nossa prática clínica.
O autor declara não ter recebido qualquer incentivo para a 
publicação deste artigo; declara fazer parte de advisory boards 
dos laboratórios Janssen, Abbott e P¿ zer.
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